Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +26.98%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.60%
#5 Pharos Pharos +15.97%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Taiko Taiko +13.85%
#9 Manadia Manadia +13.47%
#10 ROLL ROLL +13.27%
Coin of the day
Orochi Network Orochi Network
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rank in Stocks #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Share Price
$50.93
Market Cap
$226.32B
Change (1 day)
2.54%
Change (1 year)
-26.19%
Country
DK
Trade Novo Nordisk A/S (NVO)

Category

Healthcare
Earnings for Novo Nordisk A/S (NVO)
Earnings in Mar 2026 TTM: $24.72B
According to Novo Nordisk A/S latest financial reports the company's current earnings are $24.72B. In 2024 the company made an earning of $17.75B, an increase over its 2023 earnings that were of $15.50B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Novo Nordisk A/S from 2000 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -79.10%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -79.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -91.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -94.01%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
$586.40M -97.63%
US